Researchers suggest that tailoring interventions to symptom clusters and chemotherapy course may be best management strategy.

Dr. George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just days after he was placed on administrative leave while federal officials ...